Picardi Marco, Giordano Claudia, Trastulli Fabio, Leone Aldo, Della Pepa Roberta, Pugliese Novella, Iula Rossella, Delle Cave Giuseppe, Rascato Maria Gabriella, Esposito Maria, Vigliar Elena, Troncone Giancarlo, Mascolo Massimo, Russo Daniela, Persico Marcello, Pane Fabrizio
Department of Clinical Medicine and Surgery, Federico II University Medical School, Via Sergio Pansini 5, 80131 Naples, Italy.
Department of Advanced Biomedical Sciences, Federico II University Medical School Naples, Via Sergio Pansini 5, 80131 Naples, Italy.
Cancers (Basel). 2022 Apr 11;14(8):1927. doi: 10.3390/cancers14081927.
Contrast-enhanced ultrasonography (CEUS) use for detecting lymphoma in the spleen was questioned because of the risk of its inadequate diagnostic accuracy. The aim of the present study was to validate CEUS exam for the identification of spleen involvement by lymphoma in patients at risk. A total of 260 nodules from the spleens of 77 patients with lymph node biopsy-proven non-Hodgkin lymphoma (NHL; n = 44) or Hodgkin lymphoma (HL; n = 33) at staging (n = 56) or follow-up (n = 21) were collected in a hematology Italian center and retrospectively analyzed. Nodules were classified as malignant lymphoma if ≥0.5 cm (long axis) with arterial phase isoen-hancement and early (onset <60 s after contrast agent injection) wash-out of marked (≤120 s after contrast agent injection) degree. Other perfusional combinations at CEUS scans qualified lesions as benign or inconclusive. Diagnostic reference standard was clinical laboratory imaging monitoring for 230 nodules, and/or histology for 30 nodules. The median nodule size was 1.5 cm (range 0.5−7 cm). According to the reference standard, 204 (78%) nodules were lymphomas (aggressive-NHL (a-NHL), 122; classic-HL (c-HL), 65; indolent (i)-NHL, 17) and 56 (22%) were benign (inflammation, infection, and/or mesenchymal) lesions. Sensitivity, specificity, positive predictive value, negative predictive value, and overall diagnostic accuracy of CEUS for detecting lymphoma in the spleen were 95%, 100%, 100%, 85%, and 96%, respectively. Marked wash-out range of 55−90 s (median, 74 s), 92−120 s (median, 100 s), and 101−120 s (median, 114.5 s) was 100%, 96.6%, and 77% predictive of a-NHL, c-HL, and i-NHL splenic nodular infiltration, respectively. The CEUS perfusional pattern of arterial phase isoenhancement with early wash-out of marked degree was highly accurate for the detection of lymphomatous invasion of spleen in patients at risk, enabling its use for a confident non-invasive diagnosis.
由于对比增强超声检查(CEUS)诊断准确性不足的风险,其用于检测脾脏淋巴瘤受到质疑。本研究的目的是验证CEUS检查在识别有风险患者脾脏淋巴瘤受累情况方面的有效性。在意大利一家血液学中心收集了77例经淋巴结活检证实为非霍奇金淋巴瘤(NHL;n = 44)或霍奇金淋巴瘤(HL;n = 33)患者在分期(n = 56)或随访(n = 21)时脾脏的260个结节,并进行回顾性分析。如果结节长轴≥0.5 cm,动脉期等增强且在造影剂注射后早期(开始时间<60秒)出现明显(≤120秒)程度的廓清,则将其分类为恶性淋巴瘤。CEUS扫描的其他灌注组合将病变判定为良性或不确定。230个结节的诊断参考标准为临床实验室影像学监测,30个结节为组织学检查。结节大小中位数为1.5 cm(范围0.5 - 7 cm)。根据参考标准,204个(78%)结节为淋巴瘤(侵袭性NHL(a - NHL),122个;经典HL(c - HL),65个;惰性(i)- NHL,17个),56个(22%)为良性(炎症、感染和/或间质性)病变。CEUS检测脾脏淋巴瘤的敏感性、特异性、阳性预测值、阴性预测值和总体诊断准确性分别为95%、100%、100%、85%和96%。55 - 90秒(中位数,74秒)、92 - 120秒(中位数,100秒)和101 - 120秒(中位数,114.5秒)的明显廓清范围分别对a - NHL、c - HL和i - NHL脾脏结节浸润的预测率为100%、96.6%和77%。动脉期等增强且早期出现明显程度廓清的CEUS灌注模式对于检测有风险患者脾脏的淋巴瘤浸润具有高度准确性,使其可用于可靠的非侵入性诊断。